These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 8780847)
21. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. Rinaldo CR; Liebmann JM; Huang XL; Fan Z; Al-Shboul Q; McMahon DK; Day RD; Riddler SA; Mellors JW J Infect Dis; 1999 Feb; 179(2):329-36. PubMed ID: 9878015 [TBL] [Abstract][Full Text] [Related]
22. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people. Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823 [TBL] [Abstract][Full Text] [Related]
23. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus. Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645 [TBL] [Abstract][Full Text] [Related]
24. [Anti-retroviral treatment. Treatment in special situations: acute infection, pregnancy, central nervous system involvement, thrombocytopenia, accidental exposure]. Iribarren JA; Miralles P; Baraia J; Díez F Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():36-43. PubMed ID: 9053026 [No Abstract] [Full Text] [Related]
25. Decline of HIV-1 RNA in cerebrospinal fluid during zidovudine treatment. Portegies P; Danner SA; Enting RH; Meilof J; de Wolf F; Goudsmit J Antivir Ther; 1996 Aug; 1(3):195. PubMed ID: 11322255 [No Abstract] [Full Text] [Related]
26. [Antiretroviral treatment. Present and future of the combinations]. Gatell-Artigas JM Rev Neurol; 1996 Dec; 24(136):1627-31. PubMed ID: 9064189 [TBL] [Abstract][Full Text] [Related]
28. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV. Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656 [TBL] [Abstract][Full Text] [Related]
29. Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. Chaisilwattana P; Chokephaibulkit K; Chalermchockcharoenkit A; Vanprapar N; Sirimai K; Chearskul S; Sutthent R; Opartkiattikul N Clin Infect Dis; 2002 Dec; 35(11):1405-13. PubMed ID: 12439805 [TBL] [Abstract][Full Text] [Related]
30. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy. Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254 [TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals. Raboud JM; Montaner JS; Rae S; Kahn J; Hammer SM; Katzenstein DA; Pavia A; Dolin R; Hughes MD; Cross A; Beltangady M; Gatell J; Dunkle L; Smaldone L Antivir Ther; 1997 Dec; 2(4):237-47. PubMed ID: 11327443 [TBL] [Abstract][Full Text] [Related]
32. Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen. Tanuma J; Ishizaki A; Gatanaga H; Kikuchi Y; Kimura S; Hiroe M; Oka S Clin Infect Dis; 2003 Oct; 37(7):e109-11. PubMed ID: 13130421 [TBL] [Abstract][Full Text] [Related]
33. Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors. Dietrich U; Ruppach H; Gehring S; Knechten H; Knickmann M; Jäger H; Wolf E; Husak R; Orfanos CE; Brede HD; Rübsamen-Waigmann H; von Briesen H AIDS; 1997 Oct; 11(12):1532-3. PubMed ID: 9342084 [No Abstract] [Full Text] [Related]
34. Chorea as a form of presentation of human immunodeficiency virus-associated dementia complex. Pardo J; Marcos A; Bhathal H; Castro M; Varea de Seijas E Neurology; 1998 Feb; 50(2):568-9. PubMed ID: 9484405 [No Abstract] [Full Text] [Related]
35. [Azidothymidine and the nervous system]. Riedel RR; Bader L; Gürtler L; Eberle J; Günther W; Naber D Fortschr Med; 1991 May; 109(14):302-6. PubMed ID: 2071083 [TBL] [Abstract][Full Text] [Related]
36. The overlooked epidemic: HIV in older adults. Whipple B; Scura KW Am J Nurs; 1996 Feb; 96(2):22-8; quiz 29. PubMed ID: 8629694 [No Abstract] [Full Text] [Related]
37. Does brain penetration of anti-HIV drugs matter? Marra CM; Booss J Sex Transm Infect; 2000 Feb; 76(1):1-2. PubMed ID: 10817058 [No Abstract] [Full Text] [Related]
38. Neuropsychological aspects of HIV infection. Egan V AIDS Care; 1992; 4(1):3-10. PubMed ID: 1562630 [TBL] [Abstract][Full Text] [Related]
39. Understanding the AIDS dementia complex (ADC). The challenge of HIV and its effects on the central nervous system. Price RW Res Publ Assoc Res Nerv Ment Dis; 1994; 72():1-45. PubMed ID: 8115708 [No Abstract] [Full Text] [Related]
40. Diffuse infiltrative CD8 lymphocytosis syndrome with predominant neurologic manifestations in two HIV-infected patients responding to zidovudine. Bachmeyer C; Dhôte R; Blanche P; Tulliez M; Sicard D; Christoforov B AIDS; 1995 Sep; 9(9):1101-2. PubMed ID: 8527087 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]